Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce

Rischio di frattura e ruolo protettivo del risedronato

Translated title of the contribution: Adjuvant treatment with anastrazole in elderly women with early breast cancer: Risk of bone fractures and protective role of risedronic acid

T. Fricia, Giuseppe Sergi, S. Lonardi, S. Marin, C. Falci, G. Pintore, S. Monfardini, A. Coin, U. Basso, E. Perissinotto, G. Enzi, E. Manzato

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of bone fractures in women over-70 with early breast cancer (EBC), and to verify usefulness of bisphosphonates. Methods. 26 elderly women aged 77.2 ± 5 ys candidate to adjuvant IAs (anastrazole 1 mg/die) for EBC were enrolled. Femoral and lumbar spine DEXA, and morphometric evaluation of vertebral bodies were performed in all patients and repeated after 1 year. 13 patients with T-score > -2 and without fractures (group A) received calcium (1000 mg/die) and 25-OH-D3 (800 UI/die). 13 patients with T-score ≤ -2 or T-score > -2 and vertebral fractures (group B) were given in addition risedronic acid (35 mg/week). Results. In group A, at 1-year follow-up, no patients showed modification of lumbar and femoral-neck BMD, while throcanter (Δ BMD: -0.021 ± 0.020, p <0.01) and total hip (Δ BMD: -0.011 ± 0.018, p <0.05) BMD decreased significantly. In group B BMD was stable in all femoral sites, while lumbar BMD significantly increased (Δ BMD L2-L4: + 0.029 ± 0.04, p <0.05). No patients developed vertebral or other fractures during the follow-up. Conclusions. Short/medium-term treatment with aromatase inhibitors in elderly women with EBC causes minimal detrimental impact on bone. Concomitant use of bisphosphonates like risedronic acid allows a safe use of aromatase inhibitors also in elderly patients.

Original languageItalian
Pages (from-to)31-36
Number of pages6
JournalGiornale di Gerontologia
Volume58
Issue number1
Publication statusPublished - Feb 2010

Fingerprint

Bone Neoplasms
Bone Fractures
Bone Density
Breast Neoplasms
Aromatase Inhibitors
Diphosphonates
Therapeutics
Thigh
Pelvic Bones
anastrozole
Risedronate Sodium
Femur Neck
Spine
Calcium
Bone and Bones

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce : Rischio di frattura e ruolo protettivo del risedronato. / Fricia, T.; Sergi, Giuseppe; Lonardi, S.; Marin, S.; Falci, C.; Pintore, G.; Monfardini, S.; Coin, A.; Basso, U.; Perissinotto, E.; Enzi, G.; Manzato, E.

In: Giornale di Gerontologia, Vol. 58, No. 1, 02.2010, p. 31-36.

Research output: Contribution to journalArticle

Fricia, T, Sergi, G, Lonardi, S, Marin, S, Falci, C, Pintore, G, Monfardini, S, Coin, A, Basso, U, Perissinotto, E, Enzi, G & Manzato, E 2010, 'Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce: Rischio di frattura e ruolo protettivo del risedronato', Giornale di Gerontologia, vol. 58, no. 1, pp. 31-36.
Fricia, T. ; Sergi, Giuseppe ; Lonardi, S. ; Marin, S. ; Falci, C. ; Pintore, G. ; Monfardini, S. ; Coin, A. ; Basso, U. ; Perissinotto, E. ; Enzi, G. ; Manzato, E. / Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce : Rischio di frattura e ruolo protettivo del risedronato. In: Giornale di Gerontologia. 2010 ; Vol. 58, No. 1. pp. 31-36.
@article{678474ced8f54701a2c2912a86e6de56,
title = "Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce: Rischio di frattura e ruolo protettivo del risedronato",
abstract = "Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of bone fractures in women over-70 with early breast cancer (EBC), and to verify usefulness of bisphosphonates. Methods. 26 elderly women aged 77.2 ± 5 ys candidate to adjuvant IAs (anastrazole 1 mg/die) for EBC were enrolled. Femoral and lumbar spine DEXA, and morphometric evaluation of vertebral bodies were performed in all patients and repeated after 1 year. 13 patients with T-score > -2 and without fractures (group A) received calcium (1000 mg/die) and 25-OH-D3 (800 UI/die). 13 patients with T-score ≤ -2 or T-score > -2 and vertebral fractures (group B) were given in addition risedronic acid (35 mg/week). Results. In group A, at 1-year follow-up, no patients showed modification of lumbar and femoral-neck BMD, while throcanter (Δ BMD: -0.021 ± 0.020, p <0.01) and total hip (Δ BMD: -0.011 ± 0.018, p <0.05) BMD decreased significantly. In group B BMD was stable in all femoral sites, while lumbar BMD significantly increased (Δ BMD L2-L4: + 0.029 ± 0.04, p <0.05). No patients developed vertebral or other fractures during the follow-up. Conclusions. Short/medium-term treatment with aromatase inhibitors in elderly women with EBC causes minimal detrimental impact on bone. Concomitant use of bisphosphonates like risedronic acid allows a safe use of aromatase inhibitors also in elderly patients.",
keywords = "Anastrazole, Early breast cancer, Elderly, Osteoporosis",
author = "T. Fricia and Giuseppe Sergi and S. Lonardi and S. Marin and C. Falci and G. Pintore and S. Monfardini and A. Coin and U. Basso and E. Perissinotto and G. Enzi and E. Manzato",
year = "2010",
month = "2",
language = "Italian",
volume = "58",
pages = "31--36",
journal = "Giornale di Gerontologia",
issn = "0017-0305",
publisher = "Pacini Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce

T2 - Rischio di frattura e ruolo protettivo del risedronato

AU - Fricia, T.

AU - Sergi, Giuseppe

AU - Lonardi, S.

AU - Marin, S.

AU - Falci, C.

AU - Pintore, G.

AU - Monfardini, S.

AU - Coin, A.

AU - Basso, U.

AU - Perissinotto, E.

AU - Enzi, G.

AU - Manzato, E.

PY - 2010/2

Y1 - 2010/2

N2 - Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of bone fractures in women over-70 with early breast cancer (EBC), and to verify usefulness of bisphosphonates. Methods. 26 elderly women aged 77.2 ± 5 ys candidate to adjuvant IAs (anastrazole 1 mg/die) for EBC were enrolled. Femoral and lumbar spine DEXA, and morphometric evaluation of vertebral bodies were performed in all patients and repeated after 1 year. 13 patients with T-score > -2 and without fractures (group A) received calcium (1000 mg/die) and 25-OH-D3 (800 UI/die). 13 patients with T-score ≤ -2 or T-score > -2 and vertebral fractures (group B) were given in addition risedronic acid (35 mg/week). Results. In group A, at 1-year follow-up, no patients showed modification of lumbar and femoral-neck BMD, while throcanter (Δ BMD: -0.021 ± 0.020, p <0.01) and total hip (Δ BMD: -0.011 ± 0.018, p <0.05) BMD decreased significantly. In group B BMD was stable in all femoral sites, while lumbar BMD significantly increased (Δ BMD L2-L4: + 0.029 ± 0.04, p <0.05). No patients developed vertebral or other fractures during the follow-up. Conclusions. Short/medium-term treatment with aromatase inhibitors in elderly women with EBC causes minimal detrimental impact on bone. Concomitant use of bisphosphonates like risedronic acid allows a safe use of aromatase inhibitors also in elderly patients.

AB - Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of bone fractures in women over-70 with early breast cancer (EBC), and to verify usefulness of bisphosphonates. Methods. 26 elderly women aged 77.2 ± 5 ys candidate to adjuvant IAs (anastrazole 1 mg/die) for EBC were enrolled. Femoral and lumbar spine DEXA, and morphometric evaluation of vertebral bodies were performed in all patients and repeated after 1 year. 13 patients with T-score > -2 and without fractures (group A) received calcium (1000 mg/die) and 25-OH-D3 (800 UI/die). 13 patients with T-score ≤ -2 or T-score > -2 and vertebral fractures (group B) were given in addition risedronic acid (35 mg/week). Results. In group A, at 1-year follow-up, no patients showed modification of lumbar and femoral-neck BMD, while throcanter (Δ BMD: -0.021 ± 0.020, p <0.01) and total hip (Δ BMD: -0.011 ± 0.018, p <0.05) BMD decreased significantly. In group B BMD was stable in all femoral sites, while lumbar BMD significantly increased (Δ BMD L2-L4: + 0.029 ± 0.04, p <0.05). No patients developed vertebral or other fractures during the follow-up. Conclusions. Short/medium-term treatment with aromatase inhibitors in elderly women with EBC causes minimal detrimental impact on bone. Concomitant use of bisphosphonates like risedronic acid allows a safe use of aromatase inhibitors also in elderly patients.

KW - Anastrazole

KW - Early breast cancer

KW - Elderly

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=77952400112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952400112&partnerID=8YFLogxK

M3 - Articolo

VL - 58

SP - 31

EP - 36

JO - Giornale di Gerontologia

JF - Giornale di Gerontologia

SN - 0017-0305

IS - 1

ER -